Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05613413 2026-01-08

LUNG-IST-127

Phase 2 Recruiting

36 enrolled

Thoracic

Metastatic Squamous Non-Small Cell Lung Carcinoma

NCT04471428 2025-12-22

CONTACT-01

Phase 3 Completed

366 enrolled 24 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01639508 2025-12-17

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Phase 2 Recruiting

86 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01708954 2025-11-28

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Phase 2 Active not recruiting

125 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

914 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05859217 2024-05-08

Cabatezo-1

Phase 2 Not yet recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00940225 2024-04-25

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Phase 2 Completed

730 enrolled 25 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT04151563 2023-12-19

CheckMate 79X

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Phase 1 Completed

210 enrolled

BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

NCT04173338 2022-06-14

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Phase 1 Terminated

9 enrolled

GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02132598 2021-03-10

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Phase 2 Terminated

5 enrolled 18 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01588821 2020-09-29

Cabozantinib in Advanced Solid Malignancies

Phase 2 Completed

37 enrolled 10 charts

GenitourinaryThoracic

Lung Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Recurrence

NCT04131543 2019-10-18

CRETA

Phase 2 Unknown

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01866410 2019-05-16

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

37 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03911193 2019-04-11

CABinMET

Phase 2 Unknown

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

FIT-001

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

LUNG-IST-127

CONTACT-01

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Cabatezo-1

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

CheckMate 79X

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Cabozantinib in Advanced Solid Malignancies

CRETA

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

CABinMET